The thiazide-sensitive Na ؉ -Cl ؊ cotransporter (NCC) is the major pathway for salt reabsorption in the distal convoluted tubule, serves as a receptor for thiazide-type diuretics, and is involved in inherited diseases associated with abnormal blood pressure. Little is known regarding the structure-function relationship in this cotransporter. Previous studies from our group reveal that mammalian NCC exhibits higher affinity for ions and thiazides than teleost NCC and suggest a role for glycosylation upon thiazide affinity. Here we have constructed a series of chimeric and mutant cDNAs between rat and flounder NCC to define the role of glycosylation status, the aminoterminal domain, the carboxyl-terminal domain, the extracellular glycosylated loop, and the transmembrane segments upon affinity for Na ؉ , Cl ؊ , and metolazone. Xenopus laevis oocytes were used as the heterologous expression system. We observed that elimination of glycosylation sites in flounder NCC did not affect the affinity of the cotransporter for metolazone. Also, swapping the amino-terminal domain, the carboxyl-terminal domain, the glycosylation sites, or the entire extracellular glycosylation loop between rat and flounder NCC had no effect upon ions or metolazone affinity. In contrast, interchanging transmembrane regions between rat and flounder NCC revealed that affinity-modifying residues for chloride are located within the transmembrane 1-7 region and for thiazides are located within the transmembrane 8 -12 region, whereas both segments seem to be implicated in defining sodium affinity. These observations strongly suggest that binding sites for chloride and thiazide in NCC are different.In the mammalian kidney, the apical thiazide-sensitive Na ϩ -Cl Ϫ cotransporter (NCC) 3 is the major pathway for salt reabsorption in the luminal membrane of the distal convoluted tubule (1, 2). NCC also serves as the target for the thiazide-type diuretics that are currently recommended by the Joint National Committee for the detection, evaluation, and treatment of high blood pressure as the first line pharmacological treatment of hypertension, either as the unique drug in patients with stage I hypertension or in combination with other anti-hypertensive agents for patients with stage II hypertension (3). The fundamental role for NCC in preserving the extracellular fluid volume and blood pressure homeostasis has been firmly established by the identification that Gitelman disease (4 -6) (an inherited disorder featuring arterial hypotension, renal salt wasting, hypokalemic metabolic alkalosis, hypocalcinuria, and hypomagnesemia) is caused by inactivating mutations of the SLC12A3 gene that encodes NCC. In addition, a loss of the negative effect of the serine/threonine kinases WNK1 and WNK4 upon NCC activity has been implicated in the pathogenesis of a salt-dependent form of human hypertension known as pseudohypoaldosteronism type II (7, 8), which features a clinical picture that is a mirror image of Gitelman disease (9), with striking sensitivity to hydrochlorot...